Jan 28, 2015 8:00 am EST CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia
Jan 12, 2015 8:00 am EST Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Nov 26, 2014 2:43 pm EST CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference
Oct 31, 2014 8:00 am EDT CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014
Sep 29, 2014 8:00 am EDT CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout
Jul 28, 2014 8:00 am EDT CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares